GlobeNewswire

LM Industries Brings Manufacturing Into the Future as World's First Digital OEM

Dela

The creators of autonomous shuttle Olli form LM Industries, a company designing and building future-looking products with partners like Allianz, Airbus and the United States Marine Corps

SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Today, the creators of the Rally Fighter and Olli announced the formation of LM Industries Group, Inc., a technology-enabled manufacturer focused on mobility products headquartered in San Francisco. LM Industries is the world's first digital OEM - which can take concepts to deployed products in under one year, all on its unique digital thread. It brings products to market in an entirely new way, designing with its global community of experts, and applying technology such as 3D printing to create and assemble products in small batches at agile microfactories. The process challenges the century-long dependency on mass manufacturing which has failed to keep up with the modern pace of technological innovation.

LM Industries creates transportation, accessibility and mobility products with customers such as Allianz Group, Airbus and the United States Marine Corps, by combining co-creation, technology, and microfactories into one modern manufacturing process that builds high-quality, low-volume products at unprecedented speeds. Its efficiency allows products to be upgradeable like software - iterated regularly and fluidly to match rapidly changing consumer preferences. Bringing Launch Forth's design and Local Motor's microfactories into one parent company provides clients with a better alternative to mass manufacturing that gets the right products into the right people's hands at the right time. With shared resources and capabilities, LM Industries will explore more ambitious and ground-breaking projects to solve the most pressing issues of our time.

"Mass manufacturing is a relic of a past era. We're in the middle of a mobility revolt where current modes of transportation are not sustainable and do not match up with rapidly changing consumer preferences," said LM Industries CEO and co-founder John B. Rogers, Jr. "We can't keep producing products the same way we've been accustomed to. The world is moving too fast for traditional manufacturing to keep up. LM Industries is on a mission to transform mass manufacturing to micro-manufacturing in order to match the new pace of technology and quickly changing consumer needs."

Allianz is partnering with Local Motors to deploy Olli in multiple cities in order to help accelerate the understanding of insurance in our shared, autonomous world. The global insurer is also designing new mobility solutions and imagining the future of mobility insurance with Launch Forth. Now Jean-Marc Pailhol, Head of Global Market Management & Distribution at Allianz SE,  joins the LM Industries board to help guide future product development and encourage strategic global partnerships.

"Because they will be pushed by pollution and traffic constraints, the large cities will be the first to accept and implement the disruptive mobility products such as autonomous or flying vehicles for public transportation. LM Industries checks all the boxes with its product features: 100% electric, 100% autonomous, 100% connected and 90% 3D printed with the ability to produce in micro factories near bigger cities," said Pailhol. "In the future, a large part of the mobility market will be taken by small factories making solutions near the cities in which they are needed. LM Industries has a real competitive advantage in that they are a step ahead of the other AV manufacturers and have a real value proposition with their microfactories.  When I met Jay Rogers nearly two years ago, I quickly recognized the relevance of his value proposition from co-creation to micro-manufacturing to mobility solutions like Olli."

The latest project from Allianz and LM Industries is an accessibility device that can be customized to match any activity level or style choices. For the past 150 years, the design of the wheelchair has remained fundamentally the same, with the same benefits and many of the same problems. With limited upgradability and the stigma of a medical device, it is time for a major shift in mass mobility that is inclusively designed with accessibility in mind, but that is also functional and fun for all people.

Other in-progress projects include a modular logistics vehicle and an unmanned cargo system with the United States Marine Corps. The success of this effort shows the elasticity and nimbleness of LM Industries to provide on-target solutions in both the commercial and military sectors. If this project continues to achieve results ahead of schedule, it stands to augment the US military with a much needed responsive capability for vehicle systems development.

"LM Industries has proven to be an agile, adaptive, and innovative partner in maturing our hybrid logistics vision," said Lieutenant General Michael G. Dana, Deputy Commandant for Installation and Logistics. "Through the Launch Forth initiative, we are developing critically needed logistical capabilities for 21st century expeditionary operations. By leveraging the power of co-creation, we will rapidly develop time sensitive, demand-driven capabilities for our Marines."

"As we have proven with Olli and other products, we can change designs based on consumer preferences in a day and custom-develop a fleet of large machines in a matter of weeks," said Rogers. "Our vision goes far beyond ground mobility; our manufacturing process can be applied to virtually any hardware product, from aviation to infrastructure, housing and other large industrial products. If Amazon created a new eco-system to monetize the long-tail of ordering things, LM Industries has created an ecosystem to monetize the long-tail of making things. Ecosystem shifts like this come once in a century."

About LM Industries
LM Industries exists to shape the future for the better. We make technology forward products using the four pillars of our innovation ecosystem: co-creation, microfactories, direct digital manufacturing, lab partnerships. We begin every product with community-powered, human-centered design and by reinventing manufacturing with microfactories, we create big things on a smaller scale for the local communities that actually need them. Our process breaks down the barriers to sustainable product development - reducing waste, consuming less energy, and ensuring we use only the materials we need. We have the unrivaled capacity to make the improbable come to life. Based in San Francisco, LM Industries is the parent company of Local Motors and Launch Forth.

Media Contact
LaunchSquad for LM Industries
lmi@launchsquad.com
415.625.8555




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LM Industries via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum